Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association: Report of 12 Cases and Review of the Literature.
Grados A, Ebbo M, Bernit E, Veit V, Mazodier K, Jean R, Coso D, Aurran-Schleinitz T, Broussais F, Bouabdallah R, Gravis G, Goncalves A, Giovaninni M, Sève P, Chetaille B, Gavet-Bongo F, Weitten T, Pavic M, Harlé JR, Schleinitz N. Grados A, et al. Among authors: broussais f. Medicine (Baltimore). 2015 Jul;94(28):e928. doi: 10.1097/MD.0000000000000928. Medicine (Baltimore). 2015. PMID: 26181571 Free PMC article. Review.
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas.
Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, El-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A. Castagna L, et al. Among authors: broussais f. Bone Marrow Transplant. 2014 Dec;49(12):1475-80. doi: 10.1038/bmt.2014.197. Epub 2014 Sep 15. Bone Marrow Transplant. 2014. PMID: 25222502
Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
Saillard C, El Cheikh J, Granata A, Coso D, Schiano JM, Bouabdallah R, Blaise D, Charrier N, Broussais F. Saillard C, et al. Among authors: broussais f. Leuk Lymphoma. 2016;57(3):714-6. doi: 10.3109/10428194.2015.1061190. Epub 2016 Jan 11. Leuk Lymphoma. 2016. PMID: 26750740 No abstract available.
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.
Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, Chabannon C, Helvig A, Xerri L, Blaise D, Bouabdallah R. Garciaz S, et al. Among authors: broussais f. Bone Marrow Transplant. 2016 Feb;51(2):319-21. doi: 10.1038/bmt.2015.257. Epub 2015 Nov 2. Bone Marrow Transplant. 2016. PMID: 26524266 No abstract available.
Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.
Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D. Garciaz S, et al. Among authors: broussais f. Bone Marrow Transplant. 2015 Jun;50(6):865-7. doi: 10.1038/bmt.2015.22. Epub 2015 Mar 2. Bone Marrow Transplant. 2015. PMID: 25730187 No abstract available.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, Aanei C, Katsahian S, Delepine R, Vaudaux S, Rouillé V, Béné MC, Dartigeas C, Van Den Neste E, Leprêtre S, Feugier P, Cartron G, Leblond V, Lévy V, Cymbalista F; French Innovative Leukemia Organization (FILO). Letestu R, et al. Leukemia. 2021 Jun;35(6):1597-1609. doi: 10.1038/s41375-020-01009-z. Epub 2020 Sep 15. Leukemia. 2021. PMID: 32934355
Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
Le KS, Thibult ML, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L, Olive D. Le KS, et al. Among authors: broussais f. Cancer Res. 2016 Aug 15;76(16):4648-60. doi: 10.1158/0008-5472.CAN-15-0589. Epub 2016 May 31. Cancer Res. 2016. PMID: 27246829
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
Vey N, Karlin L, Sadot-Lebouvier S, Broussais F, Berton-Rigaud D, Rey J, Charbonnier A, Marie D, André P, Paturel C, Zerbib R, Bennouna J, Salles G, Gonçalves A. Vey N, et al. Among authors: broussais f. Oncotarget. 2018 Apr 3;9(25):17675-17688. doi: 10.18632/oncotarget.24832. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707140 Free PMC article.
34 results